MENLO PARK, Calif.--(BUSINESS WIRE)--May 18, 2006--Geron Corp. (Nasdaq:GERN - News) announced today the addition of Laurence Elias, M.D., to the management team as Vice President, Oncology Clinical Development. Dr. Elias will oversee the company’s clinical trials of its lead anti-cancer compound, GRN163L, which is a direct inhibitor of human telomerase, and GRNVAC1, its therapeutic vaccine product targeting telomerase. His responsibilities will include the planning, design and execution of clinical trial strategies and protocols as well as the monitoring of these multi-center clinical trials.
